Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BYSI NASDAQ:FLXN NASDAQ:ONCT NASDAQ:SYRS NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$2.25-2.6%$2.14$0.98▼$3.44$93.13M0.1732,141 shs6,300 shsFLXNFlexion Therapeutics$25.020.0%$9.20$4.30▼$13.66$1.26B1.531.18 million shs4,412 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.77$1.56M1.1891,303 shsN/ASYRSSyros Pharmaceuticals$0.01+233.3%$0.03$0.00▼$6.93$241K1.318.06 million shs54,905 shsURGNUrogen Pharma$14.64+6.0%$9.88$3.42▼$18.15$636.74M1.021.09 million shs1.46 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring-2.60%0.00%-10.36%+104.55%-0.88%FLXNFlexion Therapeutics+0.33%+174.41%+174.41%+174.41%+174.41%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-92.81%SYRSSyros Pharmaceuticals+233.33%-64.14%-64.14%-62.50%-99.84%URGNUrogen Pharma+6.01%+8.52%+107.66%+44.66%-10.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASYRSSyros Pharmaceuticals4.3596 of 5 stars3.15.00.04.31.12.50.6URGNUrogen Pharma4.5652 of 5 stars4.52.00.04.52.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpring 0.00N/AN/AN/AFLXNFlexion Therapeutics 0.00N/AN/AN/AONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsideSYRSSyros Pharmaceuticals 2.20Hold$3.3336,937.04% UpsideURGNUrogen Pharma 3.00Buy$32.86124.43% UpsideCurrent Analyst Ratings BreakdownLatest URGN, SYRS, BYSI, FLXN, and ONCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.007/7/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/16/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.006/13/2025URGNUrogen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$16.006/13/2025URGNUrogen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Buy$31.006/13/2025URGNUrogen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/13/2025URGNUrogen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.006/13/2025URGNUrogen PharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $30.006/12/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/3/2025URGNUrogen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpring$1.75M51.84N/AN/A($0.37) per share-6.08FLXNFlexion Therapeutics$85.55M14.72N/AN/A($0.34) per share-73.59ONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05SYRSSyros Pharmaceuticals$386K0.63N/AN/A$0.79 per share0.01URGNUrogen Pharma$90.40M7.47N/AN/A($0.21) per share-69.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/ASYRSSyros Pharmaceuticals-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/12/2025 (Estimated)Latest URGN, SYRS, BYSI, FLXN, and ONCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A5/12/2025Q1 2025URGNUrogen Pharma-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/A2.492.49FLXNFlexion TherapeuticsN/A4.384.05ONCTOncternal TherapeuticsN/A2.392.39SYRSSyros PharmaceuticalsN/A2.252.25URGNUrogen PharmaN/A5.655.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%FLXNFlexion Therapeutics90.01%ONCTOncternal Therapeutics16.05%SYRSSyros Pharmaceuticals91.47%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%FLXNFlexion Therapeutics9.13%ONCTOncternal Therapeutics11.20%SYRSSyros Pharmaceuticals12.26%URGNUrogen Pharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionNo DataONCTOncternal Therapeutics302.96 million2.63 millionNo DataSYRSSyros Pharmaceuticals12026.83 million23.54 millionOptionableURGNUrogen Pharma20046.11 million43.76 millionOptionableURGN, SYRS, BYSI, FLXN, and ONCT HeadlinesRecent News About These CompaniesUrogen Pharma's (URGN) Buy Rating Reiterated at HC Wainwright1 hour ago | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Receives "Buy" Rating from HC WainwrightJuly 8 at 8:20 AM | marketbeat.comUroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA ApprovalsJuly 8 at 6:30 AM | tipranks.comUrogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral CapitalJuly 8 at 3:51 AM | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral CapitalJuly 7, 2025 | marketbeat.comUroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerJuly 7, 2025 | globenewswire.comUroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder CancerJuly 6, 2025 | msn.comHarel Insurance Investments & Financial Services Ltd. Cuts Position in Urogen Pharma (NASDAQ:URGN)July 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNJuly 2, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNJuly 1, 2025 | globenewswire.comURGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for InformationJune 30, 2025 | globenewswire.comURGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 30, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 27, 2025 | prnewswire.comUrogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?June 24, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by BrokeragesJune 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 23, 2025 | globenewswire.comLowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen†or the “Companyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmJune 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 22, 2025 | prnewswire.comStocks With Rising Relative Price Strength: UroGen PharmaJune 20, 2025 | msn.comUrogen Pharma (NASDAQ:URGN) Trading 10.3% Higher - Here's What HappenedJune 18, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN, SYRS, BYSI, FLXN, and ONCT Company DescriptionsBeyondSpring NASDAQ:BYSI$2.28 -0.04 (-1.52%) As of 07/10/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Oncternal Therapeutics NASDAQ:ONCT$0.53 0.00 (0.00%) As of 04/29/2025Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Syros Pharmaceuticals NASDAQ:SYRS$0.0090 +0.01 (+233.33%) As of 07/10/2025 03:58 PM EasternSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Urogen Pharma NASDAQ:URGN$14.64 +0.83 (+6.01%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$14.66 +0.02 (+0.17%) As of 07/10/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
